Re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2022-07, Vol.170, p.194-195
Main Authors: Kong, Lingti, Rong, Li, Wang, Muhua
Format: Article
Language:English
Subjects:
Cost analysis
Gene polymorphism
Irinotecan
Polymorphism
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2022.03.044